Silvia Sonzini
Silvia Sonzini has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Claire Patterson
Seda Pharmaceutical Development Services, Stockport SK8 3GX, UK
2 shared publications - Kevin Treacher
AstraZeneca
2 shared publications - Lili Cui
Institute of Pharmaceutical Science, King's College London, Franklin-Wilkins Building, 150 Stamford Street, Waterloo Campus, London SE1 9NH, UK
2 shared publications M. Jayne Lawrence
Division of Pharmacy & Optometry and the North West Centre for Advanced Drug Delivery (NoWCADD), School of Health Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, UK
2 shared publicationsMarianne Ashford
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK
2 shared publications- Marianne Ashford
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK
2 shared publications
Latest Publications
- Open Access
- 22 March 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 382, 113654
HER2-targeted star polymer conjugates for improved tumor distribution and efficacy
- 22 March 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 382, 113654
Open AccessHER2-targeted star polymer conjugates for improved tumor distribution and efficacy
- Open Access
- 14 June 2023
- Published by Wiley in Small Methods
- Vol. 7 (9) , e2201695
Understanding Intracellular Biology to Improve mRNA Delivery by Lipid Nanoparticles
Poor understanding of intracellular delivery and targeting hinders development of nucleic acid‐based therapeutics transported by nanoparticles. Utilizing a siRNA‐targeting and small molecule profiling approach with advanced imaging and machine learning biological insights is generated into the mechanism of lipid nanoparticle (MC3‐LNP) delivery of mRNA. This workflow is termed Advanced Cellular and Endocytic profiling for Intracellular Delivery (ACE‐ID). A cell‐based imaging assay and perturbation of 178 targets relevant to intracellular trafficking is used to identify corresponding effects on functional mRNA delivery. Targets improving delivery are analyzed by extracting data‐rich phenotypic fingerprints from images using advanced image analysis algorithms. Machine learning is used to determine key features correlating with enhanced delivery, identifying fluid‐phase endocytosis as a productive cellular entry route. With this new knowledge, MC3‐LNP is re‐engineered to target macropinocytosis, and this significantly improves mRNA delivery in vitro and in vivo. The ACE‐ID approach can be broadly applicable for optimizing nanomedicine‐based intracellular delivery systems and has the potential to accelerate the development of delivery systems for nucleic acid‐based therapeutics.
- 14 June 2023
- Published by Wiley in Small Methods
- Vol. 7 (9) , e2201695
Open AccessUnderstanding Intracellular Biology to Improve mRNA Delivery by Lipid Nanoparticles
Poor understanding of intracellular delivery and targeting hinders development of nucleic acid‐based therapeutics transported by nanoparticles. Utilizing a siRNA‐targeting and small molecule profiling approach with advanced imaging and machine learning biological insights is generated into the mechanism of lipid nanoparticle (MC3‐LNP) delivery of mRNA. This workflow is termed Advanced Cellular and Endocytic profiling for Intracellular Delivery (ACE‐ID). A cell‐based imaging assay and perturbation of 178 targets relevant to intracellular trafficking is used to identify corresponding effects on functional mRNA delivery. Targets improving delivery are analyzed by extracting data‐rich phenotypic fingerprints from images using advanced image analysis algorithms. Machine learning is used to determine key features correlating with enhanced delivery, identifying fluid‐phase endocytosis as a productive cellular entry route. With this new knowledge, MC3‐LNP is re‐engineered to target macropinocytosis, and this significantly improves mRNA delivery in vitro and in vivo. The ACE‐ID approach can be broadly applicable for optimizing nanomedicine‐based intracellular delivery systems and has the potential to accelerate the development of delivery systems for nucleic acid‐based therapeutics.
- Open Access
- 31 March 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 637, 122905
In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate
- 31 March 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 637, 122905
Open AccessIn depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate
- 11 November 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (3) , 844-858
The Global Characterisation of a Drug-Dendrimer Conjugate - PEGylated poly-lysine Dendrimer
- 11 November 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (3) , 844-858
The Global Characterisation of a Drug-Dendrimer Conjugate - PEGylated poly-lysine Dendrimer
- 6 April 2022
- Published by Royal Society of Chemistry (RSC) in Polymer Chemistry
- Vol. 13 (18) , 2626-2636
Investigating the properties of l-lysine dendrimers through physico-chemical characterisation techniques and atomistic molecular dynamics simulations
Poly(l-lysine) dendrimers up to generation 6 have been analysed by SEC, Taylor dispersion analysis and atomistic molecular dynamics simulations to determine their properties, in what could be considered an understudied dendrimer series.
- 6 April 2022
- Published by Royal Society of Chemistry (RSC) in Polymer Chemistry
- Vol. 13 (18) , 2626-2636
Investigating the properties of l-lysine dendrimers through physico-chemical characterisation techniques and atomistic molecular dynamics simulations
Poly(l-lysine) dendrimers up to generation 6 have been analysed by SEC, Taylor dispersion analysis and atomistic molecular dynamics simulations to determine their properties, in what could be considered an understudied dendrimer series.
- 5 January 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 14 (4) , 1480-1491
Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery
MRNA lipid nanoparticles (LNPs) are at the forefront of nucleic acid intracellular delivery, as exemplified by the recent emergency approval of two mRNA LNP-based COVID-19 vaccines. The success of an LNP product largely depends on the systematic optimisation of the four lipidic components, namely the ionisable lipid, PEG lipid, structural and helper lipids. However, the in vitro screening of novel lipidic components and LNP compositions is limited by the low-throughput of LNP preparation. To address these issues, we herein present an automated high-throughput screening platform to select novel ionisable lipids and corresponding LNPs encapsulating mRNA in vitro. This high-throughput platform employs a lab-based automated liquid handling system, amenable to high-throughput (up to 384 formulations per plate and several plates per run) and allows precise mixing and reproducible mRNA LNP preparation which ensures a direct head-to-head comparison of hundreds and even thousands of novel LNPs. Most importantly, the robotic process has been successfully applied to the screening of novel LNPs encapsulating mRNA and has identified the same novel mRNA LNP leads as those from microfluidics-mixing technology, with a correlation coefficient of 0.8751. This high-throughput platform can facilitate to narrow down the number of novel ionisable lipids to be evaluated in vivo. Moreover, this platform has been integrated into a fully-automated workflow for LNP property control, physicochemical characterisation and biological evaluation. The high-throughput platform may accelerate proprietary lipid development, mRNA LNP lead optimisation and candidate selection to advance preclinical mRNA LNP development to meet urgent global needs.
- 5 January 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 14 (4) , 1480-1491
Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery
MRNA lipid nanoparticles (LNPs) are at the forefront of nucleic acid intracellular delivery, as exemplified by the recent emergency approval of two mRNA LNP-based COVID-19 vaccines. The success of an LNP product largely depends on the systematic optimisation of the four lipidic components, namely the ionisable lipid, PEG lipid, structural and helper lipids. However, the in vitro screening of novel lipidic components and LNP compositions is limited by the low-throughput of LNP preparation. To address these issues, we herein present an automated high-throughput screening platform to select novel ionisable lipids and corresponding LNPs encapsulating mRNA in vitro. This high-throughput platform employs a lab-based automated liquid handling system, amenable to high-throughput (up to 384 formulations per plate and several plates per run) and allows precise mixing and reproducible mRNA LNP preparation which ensures a direct head-to-head comparison of hundreds and even thousands of novel LNPs. Most importantly, the robotic process has been successfully applied to the screening of novel LNPs encapsulating mRNA and has identified the same novel mRNA LNP leads as those from microfluidics-mixing technology, with a correlation coefficient of 0.8751. This high-throughput platform can facilitate to narrow down the number of novel ionisable lipids to be evaluated in vivo. Moreover, this platform has been integrated into a fully-automated workflow for LNP property control, physicochemical characterisation and biological evaluation. The high-throughput platform may accelerate proprietary lipid development, mRNA LNP lead optimisation and candidate selection to advance preclinical mRNA LNP development to meet urgent global needs.
- Open Access
- 1 November 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-13
Antisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and extracellular vesicle recycling
Next generation modified antisense oligonucleotides (ASOs) are commercially approved new therapeutic modalities, yet poor productive uptake and endosomal entrapment in tumour cells limit their broad application. Here we compare intracellular traffic of anti KRAS antisense oligonucleotide (AZD4785) in tumour cell lines PC9 and LK2, with good and poor productive uptake, respectively. We find that the majority of AZD4785 is rapidly delivered to CD63+late endosomes (LE) in both cell lines. Importantly, lysobisphosphatidic acid (LBPA) that triggers ASO LE escape is presented in CD63+LE in PC9 but not in LK2 cells. Moreover, both cell lines recycle AZD4785 in extracellular vesicles (EVs); however, AZD4785 quantification by advanced mass spectrometry and proteomic analysis reveals that LK2 recycles more AZD4785 and RNA-binding proteins. Finally, stimulating LBPA intracellular production or blocking EV recycling enhances AZD4785 activity in LK2 but not in PC9 cells thus offering a possible strategy to enhance ASO potency in tumour cells with poor productive uptake of ASOs.
- 1 November 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-13
Open AccessAntisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and extracellular vesicle recycling
Next generation modified antisense oligonucleotides (ASOs) are commercially approved new therapeutic modalities, yet poor productive uptake and endosomal entrapment in tumour cells limit their broad application. Here we compare intracellular traffic of anti KRAS antisense oligonucleotide (AZD4785) in tumour cell lines PC9 and LK2, with good and poor productive uptake, respectively. We find that the majority of AZD4785 is rapidly delivered to CD63+late endosomes (LE) in both cell lines. Importantly, lysobisphosphatidic acid (LBPA) that triggers ASO LE escape is presented in CD63+LE in PC9 but not in LK2 cells. Moreover, both cell lines recycle AZD4785 in extracellular vesicles (EVs); however, AZD4785 quantification by advanced mass spectrometry and proteomic analysis reveals that LK2 recycles more AZD4785 and RNA-binding proteins. Finally, stimulating LBPA intracellular production or blocking EV recycling enhances AZD4785 activity in LK2 but not in PC9 cells thus offering a possible strategy to enhance ASO potency in tumour cells with poor productive uptake of ASOs.
- 21 July 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (63) , 8842-8845
A simple supramolecular assay for drug detection in urine
A supramolecular colorimetric assay utilising the macrocyclic host cucurbit[7]uril with a commercial dye molecule, neutral red, was evaluated as a novel method for drug detection in urine of a model therapeutic peptide drug Octreotide.
- 21 July 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (63) , 8842-8845
A simple supramolecular assay for drug detection in urine
A supramolecular colorimetric assay utilising the macrocyclic host cucurbit[7]uril with a commercial dye molecule, neutral red, was evaluated as a novel method for drug detection in urine of a model therapeutic peptide drug Octreotide.